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Adverse Events Reported to the United
States Food and Drug Administration Related
to Caffeine-Containing Products
Andrew R. Jagim, PhD; Patrick S. Harty, MS; Karen M. Fischer, MPH;
Chad M. Kerksick, PhD; and Jacob L. Erickson, DO
Abstract
Objective: To examine differences in the frequency and severity of federally reported adverse events
between caffeine-containing and nonecaffeine-containing products while also identifying the category
of caffeine-containing products associated with the highest frequency and severity of adverse events.
Patients and Methods: All adverse event reports that met speciﬁed eligibility criteria and were submitted to the Center for Food Safety and Applied Nutrition Adverse Event Reporting System between
January 1, 2014, and June 29, 2018, were extracted. In this retrospective observational study, the most
severe adverse event experienced, an ordinal variable, was categorized into death, life-threatening,
hospitalization/disability, and emergency department visit. A nonproportional odds model was used
to compare the odds of caffeine-containing products being associated with more severe adverse events
relative to a noncaffeine group. The analysis is of data only from those reporting adverse events and
may or may not be representative of the entire population exposed to these products, which is not
known from the examined data.
Results: Energy and preworkout products saw a signiﬁcant increase in the odds of the adverse event
experienced being death rather than the other less severe outcomes relative to the noncaffeinated
group. Those products, along with weight loss products, had greater odds of the adverse event being
death or life-threatening vs the less severe outcomes relative to the noncaffeinated group.
Conclusion: Caffeine-containing products have a greater association with severe adverse events
compared with nonecaffeine-containing products. Exposure to preworkout and weight loss products
had greater odds of being associated with a more serious adverse event relative to noncaffeinated
products. Health care practitioners should use these outcomes to better inform and educate patients
about the many factors related to caffeine intake and adverse outcomes.
ª 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc. 2020;95(8):1594-1603
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he US Food and Drug Administration (FDA) Center for Food Safety
and Applied Nutrition (CFSAN) is
responsible for monitoring the safety of all
food-based products and dietary supplements, which also includes responsibility
over adverse event (AE) reports (AERs).1
In 2003, the FDA created the CFSAN
Adverse Event Reporting System (CAERS)
to serve as a self-initiated postmarket
centralized reporting system for any AERs
associated with food, dietary supplement,
or cosmetic products. In the context of this
reporting system, serious AEs are deﬁned

www.mayoclinicproceedings.org
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as (A): (1) death; (2) a life-threatening experience; (3) inpatient hospitalization; (4) a
persistent or signiﬁcant disability or incapacity; (5) a congenital anomaly, birth
defects, or other serious outcomes; or (B) requires, based on a reasonable medical judgment, a medical or surgical intervention to
prevent an outcome described under (A).1
The purpose of this system is to encourage
greater transparency regarding health concerns related to dietary supplement use and
encourage more reporting by health care
professionals. The reporting of AEs is voluntary for consumers and health professionals,

Mayo Clin Proc. n August 2020;95(8):1594-1603 n https://doi.org/10.1016/j.mayocp.2020.02.033
ª 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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whereas dietary supplement manufacturers
are mandated by law to report serious
AERs upon notiﬁcation.2
Recently, this system has been used to
identify dietary supplement products, resulting in a higher number of AERs and how the
AERs differ across age groups or between
sexes.3,4 Or et al4 indicated that dietary supplements marketed for muscle building,
energy, and weight loss were more likely to
result in a severe AE compared with vitamins in children, adolescents, and young
adults using a similar database. Similarly,
Markon et al3 compared call data from
CAERS with the US National Poison Data
System for caffeinated energy drinks and
identiﬁed 40 unique energy drink products
within CAERS, with the top 6 most
frequently speciﬁed products accounting
for 89% of all reports. Additionally, they
noted that those between the ages of 20
and 50 years had a higher number of cases
reported and more females were identiﬁed
within CAERS for being associated with
multiple product reports compared with
males.
These studies help highlight certain
product categories that may be associated
with a higher number of AERs. From this information, health care practitioners can be
more vigilant about educating and counseling their patients that certain populations
should exercise greater caution before
consuming such products and may also better understand the importance of reporting
AEs to the FDA.
Caffeine-containing products such as
multi-ingredient preworkout supplements
(MIPS), energy products, and weight loss
products are growing in popularity and are
common sources of caffeine in peoples’ diets.5-7 Collectively, these products tend to
promote beneﬁts including increased energy,
metabolic activity, and alertness while
reducing sensations of fatigue or hunger.
These product ingredient labels generally
state caffeine concentrations ranging from
60 to 400 mg per serving.8,9 However, previous studies have found discrepancies between caffeine content of the label vs the
Mayo Clin Proc. n August 2020;95(8):1594-1603
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actual caffeine amount in certain product
lots that were assessed.10-12
Although similar, each product class
tends to have a distinct ingredient proﬁle
with differing purported beneﬁts and reasons for use. For example, MIPS are a
specialized class of dietary supplements
intended to be ingested before exercise and
often include a blend of ingredients such as
caffeine, creatine, b-alanine, betaine, and Lcitrulline, all of which have varying degrees
of efﬁcacy to enhance exercise performance.8,13 Conversely, energy drinks and
“shots” tend to primarily contain caffeine, vitamins, herbs, and amino acids, all of which
have varying degrees of stimulatory and
energy-enhancing beneﬁts.9 Weight loss
products generally contain caffeine coupled
with various herbal extracts purported to
enhance metabolism, lipolysis, and fat oxidation.14,15 Because of their convenience, purported beneﬁts, and high concentration of
caffeine, these products may be more susceptible to misuse in that consumers may
consume more than the recommended
serving size.6 As a result of the combination
of multiple ingredients and concentrated
amounts of caffeine, excessive consumption
of these products may increase the likelihood of adverse effects.
To date, it is unknown whether AEs are
more likely to be associated with caffeinecontaining products compared with the
global average of food and dietary
supplementerelated AERs or the most common health outcomes. Such estimations
would require knowledge of not only how
many AEs were reported but also of how
many individuals were exposed. Further, it
is not known which category of caffeinecontaining products is associated with the
highest frequency of AERs submitted to
CFSAN.
Therefore, the objective of this study was
to examine differences in the number and
severity of AERs in CFSAN between
caffeine-containing products and nonecaffeine-containing products. A secondary aim
was to identify the category of caffeinecontaining products associated with the

https://doi.org/10.1016/j.mayocp.2020.02.033
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CAERS file 2014-2018
(n=69,358)

Exposures

Excluded (n=46,089)
• No reported product name (n=22,477)
• No industry code or unrelated industry
code (n=16,461)
• Unidentified or unreported health
outcomes (n=6,440)
• Swallowing/choking problems (n=711)
Final sample size
(n=23,269)

Allocation
Classified as caffeine containing (n=2,117)
• Coffee/tea/soda (n=158)
• Energy products (n=739)
• Weight loss (n=953)
• MIPS (n=131)

Classified as noncaffeine (n=21,152)

FIGURE. Adverse event categorization diagram. CAERS ¼ Center for Food Safety and Applied Nutrition
Adverse Event Reporting System; MIPS ¼ multi-ingredient preworkout supplement.

highest number and severity of AERs in the
CFSAN database from 2014 to 2018.
PATIENTS AND METHODS
We extracted the entire CAERS data ﬁle
from 2014 to 2018, including all AE submissions by consumers, food and dietary supplement companies, and health care
professionals directly from the FDA website.16 All AERs that were not associated
with a dietary supplement or food product
category that could potentially encompass
caffeine-containing products were subsequently removed from the analysis, that is,
any products other than those with an
FDA-assigned industry code of 54 (vitamin/
mineral/protein/unconventional diet), 41
(dietary conventional foods/meal replacements), 31 (coffee/tea), and 29 (soft drink/
water) were excluded from the data set. All
AERs with an unspeciﬁed health outcome
were also excluded from analysis.
All AEs associated with the consumption
of identiﬁed dietary supplement categories
1596
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using previously published deﬁnitions for
MIPS, energy products, weight loss products, and common caffeine-containing beverages (coffee, tea, and soda)8,9,15 were
identiﬁed, coded, and categorized by 2 independent researchers based on previously
established criteria for AERs.1,4 The categorization and exclusion process for all AEs
is outlined in the Figure (the AE categorization diagram). The classiﬁcation of products
associated with the AERs into the respective
categories based on product ingredients and
marketing descriptions was veriﬁed using
the US Department of Agriculture National
Nutrient Database (https://ndb.nal.usda.
gov/ndb/search/list?home¼true) and the
National Institutes of Health/Ofﬁce of Dietary Supplements Dietary Supplement Label
Database
(https://www.dsld.nlm.nih.gov/
dsld/index.jsp). If a search of these
resources did not yield sufﬁcient product
information, the researchers accessed the
information on relevant manufacturer
websites.

August 2020;95(8):1594-1603
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TABLE 1. AE Descriptive Characteristics for Total AEs
Total (N¼23,269)

Caffeine (N¼2117)

No Caffeine (N¼21,152)

Most severe AE experienced, no. (%)
Death
Life-threatening
Disability or hospitalization
ED visit

329
2021
7373
13,546

Product role, no. (%)
Suspect
Concomitant

15,261 (65.6%)
8008 (34.4%)

1981 (93.6%)
136 (6.4%)

13,280 (62.8%)
7872 (37.2%)

22,401 (96.3%)

1873 (88.5%)

20,528 (97.1%)

Industry, no. (%)
Vitamin/mineral/protein/
unconventional diet
Dietary conventional foods/
meal replacements
Coffee/tea
Soft drink/water

(1.4%)
(8.7%)
(31.7%)
(58.2%)

45
287
831
954

(2.1%)
(13.6%)
(39.3%)
(45.1%)

284
1734
6542
12,592

(1.3%)
(8.2%)
(30.9%)
(59.5%)

419 (1.8%)

12 (0.6%)

407 (1.9%)

145 (0.6%)
304 (1.3%)

124 (5.9%)
108 (5.1%)

21 (0.1%)
196 (0.9%)

Sorted by Subgroups, Age, and Sex
Energy Products
(N¼546)

Preworkout
(N¼103)

Coffee, Tea, or Soda
(N¼79)

Weight Loss Products
(N¼643)

Noncaffeinated Products
(N¼8803)

Age (y)
Mean  SD
43.216.6
Minimum, maximum 0.11, 91

31.010.0
16, 66

41.319.0
1, 90

40.615.0
0.02, 104

58.420.6
0, 104

Sex, no. (%)
Female
Male

391 (71.6)
155 (28.4)

13 (12.6)
90 (87.4)

47 (59.5)
32 (40.5)

464 (72.2)
179 (27.8)

5687 (64.6)
3116 (35.4)

11 (2.0)
60 (11.0)
171 (31.3)

9 (8.7)
32 (31.1)
31 (30.1)

1 (1.3)
12 (15.2)
30 (38.0)

15 (2.3)
109 (17.0)
257 (40.0)

160 (1.8)
815 (9.3)
4891 (55.6)

304 (55.7)

31 (30.1)

36 (45.6)

262 (40.8)

4891 (55.6)

Severe AE outcome, no.
(%)
Death
Life-threatening
Disability or
hospitalization
ED visit

AE ¼ adverse event; ED ¼ emergency department.

Applicable data extracted from each AER
included the date of the AE, suspected product name, sex, AE outcomes, and symptoms
associated with the AE. In accordance with
the methods of Timbo et al,1 if a single
AER contained more than one category of
caffeine-containing product, it was counted
multiple times. Occurrences with a concomitant product role are included in Table 1,
but were excluded from any further analysis.
Caffeinated products were further divided
into subgroups based on the type of product:
energy products; preworkout; coffee, tea, or
soda; and weight loss products. Observations
that had both age and sex reported were
analyzed using additional models and
Mayo Clin Proc. n August 2020;95(8):1594-1603
www.mayoclinicproceedings.org
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categorized into subgroups. Choking and
choking sensation AEs were removed, unless
it was due to an allergic reaction or other
symptoms were involved (this excluded
711 observations). Dysphagia symptoms
were retained in the data set. Because this
study used only publicly available data, it
was exempt from institutional review board
approval.
The following analysis is based solely on
the AERs reported to the CAERS database.
Baseline characteristics were calculated using mean  SD, minimum, and maximum
for continuous variables and frequency percentages for categorical variables. The primary outcome of interest was the most

https://doi.org/10.1016/j.mayocp.2020.02.033
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TABLE 2. Most Severe AE Outcome by Caffeine Subgroup

Severe AE outcome, no.
(%)
Death
Life-threatening
Disability or
hospitalization
Emergency
department visit

Energy Products
(N¼739)

Preworkout
(N¼131)

Coffee, Tea,
or Soda
(N¼158)

Weight Loss
Products
(N¼953)

No Caffeine
(N¼13,280)

15 (2.0%)
76 (10.3%)
235 (31.8%)

9 (6.9%)
40 (30.5%)
45 (34.4%)

1 (0.6%)
17 (10.8%)
41 (26.0%)

15 (1.6%)
137 (14.4%)
450 (47.2%)

250 (1.9%)
1122 (8.5%)
4263 (32.1%)

413 (55.9%)

37 (28.2%)

99 (62.7%)

351 (36.8%)

7645 (57.6%)

AE ¼ adverse event.

severe AE experienced, which was an ordinal
variable that was categorized and ranked by
the following outcomes: death, lifethreatening, hospitalization/disability, and
emergency department (ED) visit. The
main explanatory variable of interest was
the effect of the different caffeine groups.
An ordered logistic model using all observations that met the inclusion criteria
was ﬁt. Due to the caffeine group variable
not meeting the proportional odds
assumption needed for the model, a nonproportional odds model was ﬁt. For
some of the AE records, the age and sex
of the case were reported. Another ordered
logistic model was ﬁt using these observations, with age and sex included as covariates. After examining graphs of each
covariate and testing the parallelism
assumption, it was determined that a nonproportional odds model should be ﬁt for
both the unadjusted and covariateadjusted models. The reference group for
the caffeine variable in all models was
the noncaffeinated group. P¼.05 was
considered signiﬁcant in all cases and
95% CIs are reported with all odds ratios
(ORs). The statistical software used was
SAS (version 9.4; SAS Institute Inc).
RESULTS
A total of 23,269 AEs were reported from the
designated categories during 2014 to 2018,
with a higher frequency of reports associated
with noncaffeinated products (21,152 vs
2117) compared with caffeine products.
1598
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Characteristics for the observations are presented in Table 1 and are divided between
any product that contained caffeine and products that did not. Of the reports included in
this data set, 96.3% (22,401 of 23,269) were
in the vitamin/mineral/protein/unconventional diet industry code. Table 1 also summarizes the descriptive characteristics of the
subset AERs by subgroup, age, and sex.
More reports for females were recorded in
all groups except for the preworkout caffeine
group. Table 2 summarizes the most severe
AEs by subgroup.
Table 3 reports results from the nonproportional odds model comparing the different
caffeine groups. The reference group for the
caffeine group variable was the noncaffeinated group. Energy products (OR, 1.83;
95% CI, 1.16 to 2.89; P¼.01) and preworkout
products (OR, 4.90; 95% CI, 2.47 to 9.72;
P<.001) saw a signiﬁcant increase in the
odds of the AE experience being death rather
than the other less severe outcomes
compared with the noncaffeinated group.
Those products, along with weight loss products, had greater odds of the AE being death
or life-threatening vs the less severe outcomes
compared with the noncaffeinated group. Energy products had 1.46 times the odds of having the 2 most serious outcomes compared
with noncaffeinated products. Weight loss
products had 1.26 times the odds and preworkout products had 1.75 times the odds
of the AE being death or life-threatening vs
the less severe outcomes compared with the
noncaffeinated group.

August 2020;95(8):1594-1603

n
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TABLE 3. Ordered Logistic Regression; Nonproportional Odds Model (N¼15,261)a
Severe AE
b

Energy products

b

Preworkout

Coffee, tea, or sodab

Weight loss productsb

Odds Ratio (95% CI)

P

Death vs < death

1.83 (1.16-2.89)

.01

Death, life-threatening vs
hospitalization/disability, ED visit

1.46 (1.19-1.80)

<.001

> ED visit vs ED visit

1.28 (1.12-1.48)

.001

Death vs < death

4.90 (2.47-9.72)

<.001

Death, life-threatening vs
hospitalization/disability, ED visit

4.89 (3.45-6.92)

<.001

> ED visit vs ED visit

3.13 (2.21-4.45)

<.001

Death vs < death

0.44 (0.06-3.12)

.41

Death, life-threatening vs
hospitalization/disability, ED visit

1.26 (0.79-2.02)

.33

> ED visit vs ED visit

0.84 (0.62-1.16)

.29

Death vs < death

1.14 (0.68-1.93)

.92

Death, life-threatening vs
hospitalization/disability, ED visit

1.75 (1.47-2.10)

<.001

> ED visit vs ED visit

2.52 (2.21-2.88)

<.001

< ¼ health outcome regarded as less severe than; > ¼ health outcome regarded as more severe than; AE ¼ adverse event;
ED ¼ emergency department.
b
Reference group is noncaffeinated group.
a

Both the unadjusted and adjusted nonproportional odds models that included age
and sex as covariates are reported in
Table 4. The unadjusted model with sex as
the independent variable shows signiﬁcantly
decreased odds of the more severe AEs in
females compared with males, with 0.24
times the odds for death vs all other outcomes, 0.54 times the odds for death and
life-threatening vs all other outcomes, and
0.69 times the odds for more severe AEs vs
AEs that required only an ED visit.
In the unadjusted model with age, for
every 1-year increase in age, the odds of
experiencing a more severe AE that ended
in death or was life-threatening compared
with less severe AEs was signiﬁcantly lower.
This was also seen for age when comparing
the outcome of any AE more severe than
an ED visit, but no signiﬁcant difference
when comparing death vs all other AEs.
The unadjusted model containing the group
variable had similar results to the model in
Table 3, which used all reports regardless
of whether age and sex were recorded. For
every ordinal outcome, the preworkout
group had signiﬁcantly higher odds of
Mayo Clin Proc. n August 2020;95(8):1594-1603
www.mayoclinicproceedings.org

n

having a more severe AE than the noncaffeinated group (OR, 5.17; OR, 5.21; and OR,
2.90). Weight loss products had signiﬁcantly
higher odds than the noncaffeinated group
when the outcome was death or lifethreatening AE vs all others (OR, 1.92) or
more severe AEs vs an ED visit (OR, 1.82).
Table 4 also includes the full model in
which all covariates are adjusted for.
Females had consistently signiﬁcantly lower
odds of having a more severe AE than males.
The age category was signiﬁcant when
comparing death vs other outcomes and
also when comparing death and lifethreatening vs other outcomes, but the
odds were in different directions. When the
outcomes of death and life-threatening
were combined and compared with the
disability, hospitalization, and ED visit
groups, for every unit increase in age, the
odds of being in the more severe groups
decreased (OR, 0.99; 95% CI, 0.98 to 0.99;
P<.001). Preworkout and weight loss products had greater odds of having a more
serious AE than the noncaffeinated group.
For the ordinal outcome of death vs a less
serious AE, the preworkout subgroup was

https://doi.org/10.1016/j.mayocp.2020.02.033
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TABLE 4. Ordered Logistic Regression With Age and Sex Included as Covariates; Nonproportional Odds Models (N¼10,174)a
Unadjusted Modelsb
Severe AE
Female vs male

Age

Energy productsd

Preworkoutd

Coffee, tea, or sodad

Weight loss productsd

Adjusted Modelc

Odds Ratio (95% CI)

P

Odds Ratio (95% CI)

P

Death vs < death

0.24 (0.18-0.32)

<.001

0.23 (0.17-0.32)

<.001

Death, life-threatening vs
hospitalization/disability, ED visit

0.54 (0.48-0.61)

<.001

0.57 (0.50-0.64)

<.001

> ED visit vs ED visit

0.69 (0.63-0.74)

<.001

0.70 (0.64-0.76)

<.001

Death vs < death

1.00 (0.99-1.01)

.80

1.00 (1.00-1.01)

.23

Death, life-threatening vs
hospitalization/disability, ED visit

0.98 (0.98-0.99)

<.001

0.99 (0.98-0.99)

<.001

> ED visit vs ED visit

0.99 (0.99-1.00)

<.001

1.00 (0.99-1.00)

<.001

Death vs < death

1.11 (0.60-2.06)

.74

1.03 (0.56-1.91)

.92

Death, life-threatening vs
hospitalization/disability, ED visit

1.20 (0.93-1.55)

.17

1.04 (0.80-1.35)

.77

> ED visit vs ED visit

1.00 (0.84-1.18)

.96

0.96 (0.80-1.14)

.61

Death vs < death

5.17 (2.56-10.43)

<.001

3.05 (1.47-6.31)

.003

Death, life-threatening vs
hospitalization/disability, ED visit

5.21 (3.56-7.92)

<.001

2.76 (1.83-4.16)

<.001

> ED visit vs ED visit

2.90 (1.90-4.43)

<.001

2.12 (1.38-3.25)

.001

Death vs < death

0.69 (0.10-5.01)

.72

0.71 (0.10-5.14)

.74

Death, life-threatening vs
hospitalization/disability, ED visit

1.58 (0.87-2.88)

.13

1.25 (0.69-2.29)

.47

> ED visit vs ED visit

1.49 (0.96-2.33)

.08

1.36 (0.87-2.12)

.18

Death vs < death

1.29 (0.76-2.20)

.35

1.60 (0.93-2.76)

.09

Death, life-threatening vs
hospitalization/disability, ED visit

1.92 (1.56-2.36)

<.001

1.66 (1.34-2.05)

<.001

> ED visit vs ED visit

1.82 (1.55-2.14)

<.001

1.72 (1.46-2.04)

<.001

< ¼ health outcome regarded as less severe than; > ¼ health outcome regarded as more severe than; AE ¼ adverse event; ED ¼ emergency department.
b
Univariate unadjusted models for each covariate.
c
Adjusted model that includes all covariates.
d
Reference group is noncaffeinated group.
a

associated with 3.05 times the odds of death
vs a less serious AE compared with the noncaffeinated group. The odds of having a
more severe AE that was death or lifethreatening was 2.76 times the odds for preworkout compared with the noncaffeinated
group. Preworkout also had signiﬁcantly
higher odds of having an AE more severe
than an ED visit compared with the noncaffeinated group (OR, 2.12). Weight loss products had 1.66 times the odds of a severe AE
than the noncaffeinated group when the
outcome was death or life-threatening vs a
less severe AE and 1.72 times the odds of
an AE more severe than an ED visit.

1600

Mayo Clin Proc.

n

DISCUSSION
Results of the current study indicate that
during 2014 to 2018, AERs associated with
noncaffeine product represented a greater
number of total AEs (91%; 21,152 of
23,269) compared with caffeine-containing
products, regardless of industry code. However, there was a higher relative frequency
for the most severe 2 categories of AEs
(death and life-threatening) associated with
exposure to caffeine-containing products.
The AEs associated with products marketed
as “energy enhancing” and “weight loss” represented the highest percentage of AEs from
the caffeine-containing subgroups.

August 2020;95(8):1594-1603
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Previous studies have reported a nearly
2-fold increase in ED visits as a result of energy drink exposure from 2007 to 2011, with
1 in 10 visits resulting in hospitalization.17
Similarly, a recent study found an average
of 1943 to 2071 (15% to 16%) calls per
year to the National Poison Data System
associated with exposure to caffeinated energy drinks.3 These AERs relating to caffeine
and energy drinks are not limited to adult
populations as a previous investigation using
a similar AE database reported that products
marketed for energy and weight loss, which
commonly include caffeine, were associated
with 2.6 times the odds for severe medical
events compared with vitamins in individuals between the ages of 11 and 25 years.4
When adolescent and young adult ED patients were surveyed regarding their energy
drink and caffeine use, coffee and sodas represented the most common source of
caffeine among these populations, with prevalence of use ranging from 46% to 84% of
patients reporting consumption of these
items within the previous 30 days.5 In addition, the prevalence of energy drink consumption was also within this range, with
35% of adolescents and nearly 58% of young
adults reporting consumption of energy
drinks within the previous 30 days.
Currently there is a lack of sufﬁcient information regarding the safety of long-term
consumption of these products, but these
types of analyses highlight that “energy”
products of this nature may be susceptible
to misuse or potentially be dangerous, ultimately resulting in a higher rate of AERs.
An interesting observation from the current study was that MIPS represented a
greater relative frequency of AERs resulting
in death and life-threatening health outcomes. The odds of the AE being death
rather than a less severe outcome were
approximately 5 times higher in the preworkout subgroup relative to the noncaffeinated group using the total sample and
approximately 3.1 times higher after adjusting for age and sex. It is not possible to
determine causality using such a database,
but MIPS are known to contain varying
amounts
of
caffeine,
herbs,
and
Mayo Clin Proc. n August 2020;95(8):1594-1603
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performance-enhancing amino acids,8 which
may increase the risk for AERs if consumed
in high amounts or when mixed with other
dietary supplements or prescription medications. Moreover, a higher frequency of
preworkout-related AERs was experienced
by younger males when compared with females. It is worth noting that there is also
the possibility of these types of products being more frequently contaminated with prescription drugs or off-label ingredients that
may be contraindicated for consumption, as
indicated in previous studies.18-22 For
example, there have been published cases
of illegal stimulants and methamphetamine
analogues being present in weight loss and
preworkout supplements.18,19 The inadvertent consumption of such ingredients could
lead to severe AEs if a person had an underlying medical condition or consumed excess
amounts of the product. For these reasons
and others, health care practitioners should
use information from this analysis to better
inform and educate their patients on the potential harms, particularly if these patients
exhibit any previous health history that
may be exacerbated by using such products.
Although a higher relative risk exists for
severe AEs associated with caffeinecontaining products, the high total frequency of AEs from noncaffeinated products
should not be dismissed. Kantor et al23 estimated that more than 50% of adults reported
regularly using a dietary supplement in
2012. When taking into consideration the
outcomes from this analysis and recent
trends in the sales of dietary supplements,
future research should focus on the safety
of dietary supplement use and identifying
speciﬁc categories of supplements that may
be classiﬁed as higher risk. Also worth
noting is the average age of individuals
reporting AEs from nonecaffeine-containing
products that again may warrant health care
professionals having future discussions
about dietary supplement use with older
adult patients because individuals 55 years
or older represent the age group associated
with the highest percentage of US adults
who experience AEs.1 Additionally, older
adults may be more likely to be taking
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medications that have contraindications for
combining with certain dietary supplements.
This analysis is not without limitations
as CAERS serves as a self-initiated postmarket reporting system for medical professionals, consumers, and dietary supplement
companies. It is important to note that there
is insufﬁcient medical information available
in the publicly available data sets to directly
link the AERs or speciﬁc products themselves to deaths. Therefore, these results do
not imply any cause-and-effect relationship
between caffeine-containing product use
and subsequent safety concerns or health
outcomes.
Another limitation of self-reported AEs is
that little information is available regarding
details of serving size, preexisting medical
conditions, current prescription or overthe-counter drug use, or patient medical
background, which most certainly operates
as a key confounding variable for our reported outcomes. As mentioned with previous reports of this nature,4 there is the risk
for selection bias toward more severe AEs
being reported because consumers may
ignore less severe AEs. Further, the population in this study is only patients who at
least seek some level of medical treatment
or self-report their AE and symptoms; therefore, there are no patients included in this
sample without an AE. Supplement companies are mandated to report AERs upon
notiﬁcation; however, FDA researchers
have asserted that only 2% of all
supplement-related AEs are reported in a
database such as CAERS (likely attributable
to a lack of awareness of such reporting systems). Therefore, it is possible that this database is a gross underestimation of the true
number of AEs.1 Additionally, although the
regression modeling used in the current
study may provide an estimation of the
odds of certain AE outcomes being reported
based on the respective supplement category, these results may not be representative
of the entire population because the number
of exposures is unknown. Also, an inherent
bias toward the more severe AERs and
underreporting are present.
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CONCLUSION
Results of this study indicate that although
AERs for noncaffeinated products are much
greater in number than AERs from caffeinecontaining products, AERs associated with
caffeine-containing products are more likely
to be classiﬁed as severe AERs relative to
nonecaffeine-containing products based on
reported data. Furthermore, exposure to preworkout and weight loss products had
greater odds of having a more serious AE
than the noncaffeinated products. More reports for females were recorded in all
caffeine subgroups except for the preworkout caffeine group; however, females appear
to have lower odds of having a more severe
AE than males. Additionally, young adult
males represent a higher percentage of AEs
associated with preworkout supplement
ingestion. Therefore, consumers may want
to exercise caution when consuming multiple caffeine-containing products with overlapping ingredients to avoid “polysupplementation” and reduce the likelihood
of AEs or negative interactions and are
particularly warned against doing so if they
have any current medical history or medication use (prescription or over the counter)
that could be complicated by their ingestion.
This investigation is not to be misconstrued as a condemnation of all dietary supplements or caffeine-containing products but
is intended to act as a warning to consumers
to promote safe consumption practices. If a
person is insistent on consuming a given
product similar to what was examined in
this report, he or she should be made aware
of the categories of dietary supplements (ie,
energy products, weight loss supplements,
and MIPS) associated with a higher relative
risk for AEs. Additionally, consumers should
seek out companies that follow good
manufacturing practices and subscribe to
third -party testing for determination of
product quality and to ensure the absence
of any off-label ingredients or contaminants.
This strategy is increasingly important for
athletes who may be routinely drug tested
for ingredients banned for use by sporting
organizations. Last, health care professionals
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should be made more aware of this reporting
system and are encouraged to use its submission process.
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